title: Conduction velocity is regulated by sodium channel inactivation in unmyelinated axons innervating the rat cranial meninges.
abstract: Axonal conduction velocity varies according to the level of preceding impulse activity. In unmyelinated axons this typically results in a slowing of conduction velocity and a parallel increase in threshold. It is currently held that Na(+)-K(+)-ATPase-dependent axonal hyperpolarization is responsible for this slowing but this has long been equivocal. We therefore examined conduction velocity changes during repetitive activation of single unmyelinated axons innervating the rat cranial meninges. In direct contradiction to the currently accepted postulate, Na(+)-K(+)-ATPase blockade actually enhanced activity-induced conduction velocity slowing, while the degree of velocity slowing was curtailed in the presence of lidocaine (10-300 microm) and carbamazepine (30-500 microm) but not tetrodotoxin (TTX, 10-80 nm). This suggests that a change in the number of available sodium channels is the most prominent factor responsible for activity-induced changes in conduction velocity in unmyelinated axons. At moderate stimulus frequencies, axonal conduction velocity is determined by an interaction between residual sodium channel inactivation following each impulse and the retrieval of channels from inactivation by a concomitant Na(+)-K(+)-ATPase-mediated hyperpolarization. Since the process is primarily dependent upon sodium channel availability, tracking conduction velocity provides a means of accessing relative changes in the excitability of nociceptive neurons.
authors: Institute for Physiology and Pathophysiology, University of Erlangen-Nuremberg, Erlangen, Germany.
authors: Roberto
authors: R
authors: De Col
authors: Karl
authors: K
authors: Messlinger
authors: Richard W
authors: RW
authors: Carr
mesh_terms: D000818:Animals; D002220:Carbamazepine / Q000494:pharmacology; D003486:Cyanides / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D008012:Lidocaine / Q000494:pharmacology; D008094:Lithium / Q000378:metabolism; D008297:Male; D008578:Meninges / Q000166:cytology / Q000378:metabolism*; D036421:Nerve Fibers, Unmyelinated / Q000378:metabolism*; D009431:Neural Conduction / Q000502:physiology*; D009475:Neurons, Afferent / Q000378:metabolism*; D010042:Ouabain / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000378:metabolism; D015222:Sodium Channels / Q000187:drug effects / Q000378:metabolism*; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D009435:Synaptic Transmission / Q000502:physiology; D013779:Tetrodotoxin / Q000494:pharmacology
chemical_list: D003486:Cyanides; D004791:Enzyme Inhibitors; D015222:Sodium Channels; D002220:Carbamazepine; D013779:Tetrodotoxin; D010042:Ouabain; D008012:Lidocaine; D008094:Lithium; D012964:Sodium; D000254:Sodium-Potassium-Exchanging ATPase; D011188:Potassium